Oncolytic adenovirus-mediated transfer of the antisense chk2 selectively inhibits tumor growth in vitro and in vivo

Cancer Gene Therapy

Volumn 13, Issue 10, 2006, Pages 930-939

  Chen, G ^a   Zhou, J ^a   Gao, Q ^a   Huang, X ^a   Li, K ^a   Zhuang, L ^a   Huang, M ^a   Xu, G ^a   Wang, S ^a   Lu, Y ^a   Ma, D ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Adenovirus; Cancer; chk2 (checkpoint kinase 2)

Indexed keywords

ADENOVIRUS VECTOR; CHECKPOINT KINASE 2; CISPLATIN; COMPLEMENTARY DNA; ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; FEMALE; GENE SILENCING; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOMA; LOW DRUG DOSE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS MUTANT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL DIVISION; CELL LINE; DNA PRIMERS; HUMANS; MICE; PROTEIN-SERINE-THREONINE KINASES;

ADENOVIRIDAE;

EID: 33748575928     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700967     Document Type: Article

References (36)

1. Hunt K, Vorburger S. Tech.Sight. Gene therapy. Hurdles and hopes for cancer treatment. Science 2002; 297: 415-416.
2. Chu RL, Post DE, Khuri FR, Meir EGV. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299-5312.
3. Heise C, Kirn D. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000; 105: 847-851.
4. Yu D-C, Working P, Ando D. Selectively replicating oncolytic adenoviruses as cancer therapeutics. Curr Opin Mol Therap 2002; 4: 435-443.
5. Bischoff J, Kirn D, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
6. Khuri F, Nemunaitis J, Ganly I, Arseneau J, Tannock I, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
7. Hay J, Shapiro N, Sauthoff H, Heitner S, Phupakdi W, Rom W. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Hum Gene Ther 1999; 10: 579-590.
8. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134-1139.
9. Kirn D, Heise C, Williams M, Propst M, Hermiston T. Adenovirus E1A CR2 mutants as selectively-replicating agents for cancer. Presented at Cancer Gene Therapy meeting (R Sobol and K Scanlon, organizers). San Diego, CA,. 1998.
10. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff D, Kirn D. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-645.
11. Yu D, Chen Y, Dilley J, Li Y, Embry M, Zhang H et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517-525.
12. Rogulski K, Freytag S, Zhang K, Gilbert J, Paielli D, Kim J et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000; 60: 1193-1196.
13. Heise C, Lemmon M, Kirn D. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res 2000; 6: 4908-4914.
14. Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest 2000; 105: 1169-1172.
15. Wildner O, Morris J. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res 2000; 60: 4167-4174.
16. Sznol M, Lin S, Bermudes D, Zheng L, King I. Use of preferentially replicating bacteria for the treatment of cancer. J Clin Invest 2000; 105: 1027-1030.
17. Weinert T. DNA damage and checkpoint pathways: molecular anatomy and interactions with repair. Cell 1998; 94: 555-558.
18. Sorensen C, Hansen L, Dziegielewski J, Syljuasen R, Lundin C, Bartek J et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005; 7: 195-201.
19. Zhou B-BS, Sausville EA. Drug discovery targeting Chk1 and Chk2 kinases. Prog Cell Cycle Res 2003; 5: 413-421.
20. Wong C, Guminski A, Saunders N, Burgess A. Exploiting novel cell cycle targets in the development of anticancer agents. Curr Cancer Drug Targets 2005; 5: 85-102.
21. Chaturvedi P, Eng W, Zhu Y, Mattern M, Mishra R, Hurle M et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999; 18: 4047-4054.
22. Bartek J, Luk J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-429.
23. Gary K, Boyer J. Isolation, Growth, and Purification of Defective Adenovirus Deletion Mutants. Humann Press: Totowa, NJ, 1999.
24. Hermiston TW, Tollefson AE, Wold WSM. Construction of Mutations in the Adenovirus Early Region 3 (E3) Transcription Units. Humann Press: Totowa, NJ, 1999.
25. Zhou J, Gurates B, Yang S, Sebastian S, Bulun S. Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Res 2001; 61: 2328-2334.
26. Fabra A, Parada C, Vinyals A, Martin DP, Fernandez V, Sanchez-Prieto R et al. Intravascular injections of a conditional replicative adenovirus (adl118) prevent metastatic disease in human breast carcinoma xenografts. Gene Therapy 2001; 8: 1628-1634.
27. Habib N, Sarraf C, Mitry R, Havlik R, Nicholls J, Kelly M et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 2001; 12: 219-226.
28. Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 2001; 61: 5453-5460.
29. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004; 6(Suppl 1): S164-S171.
30. Stubdal H, Perin N, Lemmon M, Holman P, Bauzon M, Potter P et al. A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer Res 2003; 63: 6900-6908.
31. Carette JE, Overmeer RM, Schagen FHE, Alemany R, Barski OA, Gerritsen WR et al. Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells. Cancer Res 2004; 64: 2663-2667.
32. Pommier Y, Sordet O, Rao V, Zhang H, Kohn K. Targeting chk2 kinase: molecular interaction maps and therapeutic rationale. Curr Pharm Des 2005; 11: 2855-2872.
33. Baron M, Lewis V. Images in clinical medicine. Liver metastases from lung cancer. N Engl J Med 2001; 345: 180.
34. Venook A, Althaus B, Warren R. Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer. N Engl J Med 2000; 342: 1524.
35. Kemeny N, Huang Y, Cohen A, Shi W, Conti J, Brennan M et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-2048.
36. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.